Baolingbao Biology Co.,Ltd. (SHE:002286)

Market Cap	3.05B -23.7%
Revenue (ttm)	2.81B +11.0%
Net Income	154.40M +11.6%
EPS	0.41 +8.6%
Shares Out	380.57M
PE Ratio	19.41
Forward PE	15.11
Dividend	0.12 (1.50%)
Ex-Dividend Date	Jul 14, 2026

Volume	10,396,700
Open	8.00
Previous Close	8.01
Day's Range	7.93 - 8.07
52-Week Range	7.15 - 12.28
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Baolingbao Biology

Baolingbao Biology Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of functional sugar in China and internationally. The company offers prebiotics, including galacto-oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, and xylooligosaccharides; sugar alcohols and sources, such as erythritol, trehalose, crystallized fructose, allulose, and maltotetrasaccharide; dietary fiber comprising polydextrose and resistant dextrin; modified, waxy corn, and corn starch products; starch s...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 1,505
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002286

Financial Performance

In 2025, Baolingbao Biology's revenue was 2.75 billion, an increase of 14.54% compared to the previous year's 2.40 billion. Earnings were 150.63 million, an increase of 35.50%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 4, 2026

Data Sources Report a data error